Delisting risk
NCEL · NASDAQ · Biotechnology

NewcelX (NCEL)

Develops stem-cell-derived islet and astrocyte therapies for diabetes and ALS.

$3.48
At close+0.19 (+5.78%)

Something off on this page? Send us feedback.

EPSReportedEstimate

May '23Jun '23Dec '23May '24Oct '24May '25Oct '25Feb '26
Reported−$2.90−$0.20−$68.00−$1.40−$1.94−$26.30−$10.50$1.29
Estimate−$120.00−$6.80−$68.00−$84.00
Surprise+97.6%+97.1%0.0%+98.3%

RevenueReportedEstimate

May '23Jun '23Dec '23May '24Oct '24May '25Oct '25Feb '26
Reported
Estimate
Surprise

History

DateEstimateReportedSurprise
Sep 2026−$0.53
May 2026
Feb 2026$1.29
Oct 2025
Oct 2025−$10.50
May 2025−$26.30
Oct 2024−$1.94
Aug 2024

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
May 2024
Feb 2024−$0.21
Dec 2023
Jun 2023
May 2023
Mar 2023
Oct 2022
Jun 2022
Mar 2022
Sep 2021
May 2021
Jun 2020
Dec 2019
Jun 2019
Dec 2018
Jun 2018
Jun 2017
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Sep 2, 2026−$0.53
May 15, 2026
Feb 25, 2026$1.29−0.4%
Oct 6, 2025
Oct 4, 2025−$10.50−4.0%
May 16, 2025−$26.30+5.6%
Oct 18, 2024−$1.94−10.2%
Aug 28, 2024

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
May 15, 2024
Feb 28, 2024−$0.21
Dec 6, 2023
Jun 30, 2023
May 5, 2023
Mar 23, 2023
Oct 11, 2022
Jun 30, 2022
Mar 24, 2022
Sep 28, 2021
May 14, 2021
Jun 30, 2020
Dec 31, 2019
Jun 30, 2019
Dec 31, 2018
Jun 30, 2018
Jun 30, 2017